Academic Journal
Hypertension Caused by Lenvatinib and Everolimus in the Treatment of Metastatic Renal Cell Carcinoma
| العنوان: | Hypertension Caused by Lenvatinib and Everolimus in the Treatment of Metastatic Renal Cell Carcinoma |
|---|---|
| المؤلفون: | Mathias Alrø Fichtner Bendtsen, Daniela Grimm, Johann Bauer, Markus Wehland, Petra Wise, Nils E. Magnusson, Manfred Infanger, Marcus Krüger |
| المصدر: | International Journal of Molecular Sciences, Vol 18, Iss 8, p 1736 (2017) |
| بيانات النشر: | MDPI AG |
| سنة النشر: | 2017 |
| المجموعة: | Directory of Open Access Journals: DOAJ Articles |
| مصطلحات موضوعية: | metastatic renal cell carcinoma, lenvatinib, everolimus, hypertension, multikinase inhibitors, mTOR inhibitor, vascular endothelial growth factor, Biology (General), QH301-705.5, Chemistry, QD1-999 |
| الوصف: | Multikinase inhibitors (MKI) and mammalian target of rapamycin (mTOR) inhibitors prolong progression-free (PFS) and overall survival (OS) in the treatment of metastatic renal cell carcinoma (mRCC) by reducing angiogenesis and tumor growth. In this regard, the MKI lenvatinib and the mTOR inhibitor everolimus proved effective when applied alone, but more effective when they were administered combined. Recently, both drugs were included in clinical trials, resulting in international clinical guidelines for the treatment of mRCC. In May 2016, lenvatinib was approved by the American Food and Drug Administration (FDA) for the use in combination with everolimus, as treatment of advanced renal cell carcinoma following one prior antiangiogenic therapy. A major problem of treating mRCC with lenvatinib and everolimus is the serious adverse event (AE) of arterial hypertension. During the treatment with everolimus and lenvatinib combined, 42% of the patients developed hypertension, while 10% of the patients treated with everolimus alone and 48% of the of the lenvatinib only treated patients developed hypertension. Lenvatinib carries warnings and precautions for hypertension, cardiac failure, and other adverse events. Therefore, careful monitoring of the patients is necessary. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 1422-0067 |
| Relation: | https://www.mdpi.com/1422-0067/18/8/1736; https://doaj.org/toc/1422-0067; https://doaj.org/article/c9729d3a0b6b46dea8eb87ca1c588777 |
| DOI: | 10.3390/ijms18081736 |
| الاتاحة: | https://doi.org/10.3390/ijms18081736 https://doaj.org/article/c9729d3a0b6b46dea8eb87ca1c588777 |
| رقم الانضمام: | edsbas.4E928B03 |
| قاعدة البيانات: | BASE |
Full Text Finder | ResultId |
1 |
|---|---|
| Header |
edsbas BASE edsbas.4E928B03 871 3 Academic Journal academicJournal 871.106628417969 |
| PLink |
https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsbas&AN=edsbas.4E928B03&custid=s6537998&authtype=sso |
| FullText |
Array
(
[Availability] => 0
)
Array ( [0] => Array ( [Url] => https://doi.org/10.3390/ijms18081736# [Name] => EDS - BASE [Category] => fullText [Text] => View record in BASE [MouseOverText] => View record in BASE ) [1] => Array ( [Url] => https://resolver.ebscohost.com/openurl?custid=s6537998&groupid=main&authtype=ip,guest&sid=EBSCO:edsbas&genre=article&issn=14220067&ISBN=&volume=&issue=&date=20170101&spage=&pages=&title=International Journal of Molecular Sciences, Vol 18, Iss 8, p 1736 (2017&atitle=Hypertension%20Caused%20by%20Lenvatinib%20and%20Everolimus%20in%20the%20Treatment%20of%20Metastatic%20Renal%20Cell%20Carcinoma&id=DOI:10.3390/ijms18081736 [Name] => Full Text Finder (s6537998api) [Category] => fullText [Text] => Full Text Finder [Icon] => https://imageserver.ebscohost.com/branding/images/FTF.gif [MouseOverText] => Full Text Finder ) ) |
| Items |
Array
(
[Name] => Title
[Label] => Title
[Group] => Ti
[Data] => Hypertension Caused by Lenvatinib and Everolimus in the Treatment of Metastatic Renal Cell Carcinoma
)
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22Mathias+Alrø+Fichtner+Bendtsen%22">Mathias Alrø Fichtner Bendtsen</searchLink><br /><searchLink fieldCode="AR" term="%22Daniela+Grimm%22">Daniela Grimm</searchLink><br /><searchLink fieldCode="AR" term="%22Johann+Bauer%22">Johann Bauer</searchLink><br /><searchLink fieldCode="AR" term="%22Markus+Wehland%22">Markus Wehland</searchLink><br /><searchLink fieldCode="AR" term="%22Petra+Wise%22">Petra Wise</searchLink><br /><searchLink fieldCode="AR" term="%22Nils+E%2E+Magnusson%22">Nils E. Magnusson</searchLink><br /><searchLink fieldCode="AR" term="%22Manfred+Infanger%22">Manfred Infanger</searchLink><br /><searchLink fieldCode="AR" term="%22Marcus+Krüger%22">Marcus Krüger</searchLink> ) Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => International Journal of Molecular Sciences, Vol 18, Iss 8, p 1736 (2017) ) Array ( [Name] => Publisher [Label] => Publisher Information [Group] => PubInfo [Data] => MDPI AG ) Array ( [Name] => DatePubCY [Label] => Publication Year [Group] => Date [Data] => 2017 ) Array ( [Name] => Subset [Label] => Collection [Group] => HoldingsInfo [Data] => Directory of Open Access Journals: DOAJ Articles ) Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => <searchLink fieldCode="DE" term="%22metastatic+renal+cell+carcinoma%22">metastatic renal cell carcinoma</searchLink><br /><searchLink fieldCode="DE" term="%22lenvatinib%22">lenvatinib</searchLink><br /><searchLink fieldCode="DE" term="%22everolimus%22">everolimus</searchLink><br /><searchLink fieldCode="DE" term="%22hypertension%22">hypertension</searchLink><br /><searchLink fieldCode="DE" term="%22multikinase+inhibitors%22">multikinase inhibitors</searchLink><br /><searchLink fieldCode="DE" term="%22mTOR+inhibitor%22">mTOR inhibitor</searchLink><br /><searchLink fieldCode="DE" term="%22vascular+endothelial+growth+factor%22">vascular endothelial growth factor</searchLink><br /><searchLink fieldCode="DE" term="%22Biology+%28General%29%22">Biology (General)</searchLink><br /><searchLink fieldCode="DE" term="%22QH301-705%2E5%22">QH301-705.5</searchLink><br /><searchLink fieldCode="DE" term="%22Chemistry%22">Chemistry</searchLink><br /><searchLink fieldCode="DE" term="%22QD1-999%22">QD1-999</searchLink> ) Array ( [Name] => Abstract [Label] => Description [Group] => Ab [Data] => Multikinase inhibitors (MKI) and mammalian target of rapamycin (mTOR) inhibitors prolong progression-free (PFS) and overall survival (OS) in the treatment of metastatic renal cell carcinoma (mRCC) by reducing angiogenesis and tumor growth. In this regard, the MKI lenvatinib and the mTOR inhibitor everolimus proved effective when applied alone, but more effective when they were administered combined. Recently, both drugs were included in clinical trials, resulting in international clinical guidelines for the treatment of mRCC. In May 2016, lenvatinib was approved by the American Food and Drug Administration (FDA) for the use in combination with everolimus, as treatment of advanced renal cell carcinoma following one prior antiangiogenic therapy. A major problem of treating mRCC with lenvatinib and everolimus is the serious adverse event (AE) of arterial hypertension. During the treatment with everolimus and lenvatinib combined, 42% of the patients developed hypertension, while 10% of the patients treated with everolimus alone and 48% of the of the lenvatinib only treated patients developed hypertension. Lenvatinib carries warnings and precautions for hypertension, cardiac failure, and other adverse events. Therefore, careful monitoring of the patients is necessary. ) Array ( [Name] => TypeDocument [Label] => Document Type [Group] => TypDoc [Data] => article in journal/newspaper ) Array ( [Name] => Language [Label] => Language [Group] => Lang [Data] => English ) Array ( [Name] => ISSN [Label] => ISSN [Group] => ISSN [Data] => 1422-0067 ) Array ( [Name] => NoteTitleSource [Label] => Relation [Group] => SrcInfo [Data] => https://www.mdpi.com/1422-0067/18/8/1736; https://doaj.org/toc/1422-0067; https://doaj.org/article/c9729d3a0b6b46dea8eb87ca1c588777 ) Array ( [Name] => DOI [Label] => DOI [Group] => ID [Data] => 10.3390/ijms18081736 ) Array ( [Name] => URL [Label] => Availability [Group] => URL [Data] => https://doi.org/10.3390/ijms18081736<br />https://doaj.org/article/c9729d3a0b6b46dea8eb87ca1c588777 ) Array ( [Name] => AN [Label] => Accession Number [Group] => ID [Data] => edsbas.4E928B03 ) |
| RecordInfo |
Array
(
[BibEntity] => Array
(
[Identifiers] => Array
(
[0] => Array
(
[Type] => doi
[Value] => 10.3390/ijms18081736
)
)
[Languages] => Array
(
[0] => Array
(
[Text] => English
)
)
[Subjects] => Array
(
[0] => Array
(
[SubjectFull] => metastatic renal cell carcinoma
[Type] => general
)
[1] => Array
(
[SubjectFull] => lenvatinib
[Type] => general
)
[2] => Array
(
[SubjectFull] => everolimus
[Type] => general
)
[3] => Array
(
[SubjectFull] => hypertension
[Type] => general
)
[4] => Array
(
[SubjectFull] => multikinase inhibitors
[Type] => general
)
[5] => Array
(
[SubjectFull] => mTOR inhibitor
[Type] => general
)
[6] => Array
(
[SubjectFull] => vascular endothelial growth factor
[Type] => general
)
[7] => Array
(
[SubjectFull] => Biology (General)
[Type] => general
)
[8] => Array
(
[SubjectFull] => QH301-705.5
[Type] => general
)
[9] => Array
(
[SubjectFull] => Chemistry
[Type] => general
)
[10] => Array
(
[SubjectFull] => QD1-999
[Type] => general
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Hypertension Caused by Lenvatinib and Everolimus in the Treatment of Metastatic Renal Cell Carcinoma
[Type] => main
)
)
)
[BibRelationships] => Array
(
[HasContributorRelationships] => Array
(
[0] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Mathias Alrø Fichtner Bendtsen
)
)
)
[1] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Daniela Grimm
)
)
)
[2] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Johann Bauer
)
)
)
[3] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Markus Wehland
)
)
)
[4] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Petra Wise
)
)
)
[5] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Nils E. Magnusson
)
)
)
[6] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Manfred Infanger
)
)
)
[7] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Marcus Krüger
)
)
)
)
[IsPartOfRelationships] => Array
(
[0] => Array
(
[BibEntity] => Array
(
[Dates] => Array
(
[0] => Array
(
[D] => 01
[M] => 01
[Type] => published
[Y] => 2017
)
)
[Identifiers] => Array
(
[0] => Array
(
[Type] => issn-print
[Value] => 14220067
)
[1] => Array
(
[Type] => issn-locals
[Value] => edsbas
)
[2] => Array
(
[Type] => issn-locals
[Value] => edsbas.oa
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => International Journal of Molecular Sciences, Vol 18, Iss 8, p 1736 (2017
[Type] => main
)
)
)
)
)
)
)
|
| IllustrationInfo |